Spiropiperidine derivatives as melanocortin receptor agonists

A compound having the formula I:

• wherein
• Cy2 is a six-membered aromatic ring containing 0 or 1N atom or cyclohexane;
• Q is
• X is CH2, CHCO2Rb, CHSO2Ra, CHC(O)N(Rb)2, NRb, NSO2Ra, NSO2N(Rb)2, NCORa, NCON(Rb)2, CHN(Rb)CORa, CHN(Rb)SO2Ra, CHCH2ORb, or CH(CH2)-heteroaryl;
• Y is (CH2)r, CH—C1-8alkyl, or C═O;
• R1 is H, C1-8alkyl, CH(Rb)-aryl, CH(Rb)-heteroaryl, (CH2)n—C5-6cycloalkyl in which aryl and heteroaryl are optionally substituted by one or two Rcgroups;
• R2 is H or halo;
• Ra is Rb, (CH2)nN(Rb)2, (CH2)nN(Rb)C(═NRd)NRb, (CH2)nNH-2-pyridyl, (CH2)nNH-2-imidazolyl, (CH2)nNH-2-thiazolyl, (CH2)nNH-2-pyrimidinyl,
• Rb is H, C1-8alkyl, (CH2)naryl, (CH2)nheteroaryl, C3-6cycloalkyl;
• or 2 Rb together with the nitrogen atom to which they are attached form a 5- or 6-membered ring optionally containing an additional heteroatom selected from O, S, and NR1;
• Rc is Rb, halo, ORb, NHSO2Rb, N(Rb)2, CN, NO2, SO2N(Rb)2, SO2Rb, CF3, OCF3;
• or two Rc groups attached to adjacent carbon atoms together form methylenedioxy;
• Rd is H, NO2, or CN;
• Cy is aryl or 5- or 6-membered carbocyclyl;
• n is 0 to 3;
• m, p and q are independently 0, 1 or 2;
• r is 1, 2 or 3;
• or a pharmaceutically acceptable salt thereof.